Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more
Market Cap & Net Worth: Kamada (KMDA)
Kamada (NASDAQ:KMDA) has a market capitalization of $512.79 Million ($512.79 Million) as of March 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #18877 globally and #6981 in its home market, demonstrating a -1.00% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kamada's stock price $8.89 by its total outstanding shares 57681420 (57.68 Million).
Kamada Market Cap History: 2015 to 2026
Kamada's market capitalization history from 2015 to 2026. Data shows growth from $239.15 Million to $512.79 Million (8.45% CAGR).
Index Memberships
Kamada is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.00% | #516 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1736 of 3165 |
Weight: Kamada's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Kamada Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kamada's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.08x
Kamada's market cap is 2.08 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
18.63x
Kamada's market cap is 18.63 times its annual earnings
10.35x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $314.36 Million | $77.49 Million | -$6.73 Million | 4.06x | N/A |
| 2017 | $273.99 Million | $102.83 Million | $6.90 Million | 2.66x | 39.70x |
| 2018 | $288.41 Million | $114.47 Million | $22.30 Million | 2.52x | 12.94x |
| 2019 | $393.96 Million | $127.19 Million | $22.25 Million | 3.10x | 17.71x |
| 2020 | $373.78 Million | $133.25 Million | $17.14 Million | 2.81x | 21.81x |
| 2021 | $379.54 Million | $103.64 Million | -$2.23 Million | 3.66x | N/A |
| 2022 | $231.30 Million | $129.34 Million | -$2.32 Million | 1.79x | N/A |
| 2023 | $353.01 Million | $142.52 Million | $8.28 Million | 2.48x | 42.61x |
| 2024 | $351.28 Million | $160.95 Million | $14.46 Million | 2.18x | 24.29x |
| 2025 | $407.23 Million | $195.34 Million | $21.86 Million | 2.08x | 18.63x |
Competitor Companies of KMDA by Market Capitalization
Companies near Kamada in the global market cap rankings as of March 18, 2026.
Key companies related to Kamada by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Kamada Historical Marketcap From 2015 to 2026
Between 2015 and today, Kamada's market cap moved from $239.15 Million to $ 512.79 Million, with a yearly change of 8.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $512.79 Million | +25.92% |
| 2025 | $407.23 Million | +15.93% |
| 2024 | $351.28 Million | -0.49% |
| 2023 | $353.01 Million | +52.62% |
| 2022 | $231.30 Million | -39.06% |
| 2021 | $379.54 Million | +1.54% |
| 2020 | $373.78 Million | -5.12% |
| 2019 | $393.96 Million | +36.60% |
| 2018 | $288.41 Million | +5.26% |
| 2017 | $273.99 Million | -12.84% |
| 2016 | $314.36 Million | +31.45% |
| 2015 | $239.15 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Kamada was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $512.79 Million USD |
| MoneyControl | $512.79 Million USD |
| MarketWatch | $512.79 Million USD |
| marketcap.company | $512.79 Million USD |
| Reuters | $512.79 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.